{"title": "Non-severe vs severe symptomatic COVID-19: 104 cases from the outbreak on the cruise ship \u201cDiamond Princess\u201d in Japan", "doi": "10.1101/2020.03.18.20038125", "citation_id": "2020.03.18.20038125v1", "date": "2020-03-20", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.18.20038125", "abstract": "<p>Background\nThe ongoing outbreak of 2019 novel coronavirus disease (COVID-19) is a global threat. Clarifying its clinical features such as risk factors for disease progression is a pressing issue. We analyzed the difference between non-severe and severe cases with COVID-19 as a result of the mass infection on a cruise ship \u201cDiamond Princess\u201d in Japan.\nMethods\nIn this retrospective, single-center study, total 104 cases of laboratory-confirmed COVID-19 were enrolled from the mass infection on the cruise ship from 11th to 25th Feb, 2020, at Self-Defense Forces Central Hospital in Japan. Clinical records, laboratory data, and radiological findings were collected and analyzed. Clinical outcomes were followed up until 26th Feb, 2020.\nFindings\nOf the 104 patients, 47 were male. The median age was 68 years. During the observation period, eight patients deteriorated into the severe cases. Finally, 76 and 28 patients were classified as non-severe (asymptomatic, mild), and severe cases, respectively. Chest CT abnormalities were found in 43 in non-severe cases and 23 in severe cases. The prevalence of consolidation on chest CT scan and lymphopenia on the admission day was significantly higher in severe cases and in the eight cases which worsened into severe disease during the observation period.\nInterpretation\nThe high proportion of non-severe cases corrects the assessment of the trend of the outbreak. Consolidation on chest CT scan and lymphopenia were possible risk factors for deterioration of COVID-19 and contribute to the clinical management. \n\nFunding\nNot applicable.</p>", "twitter_description": "Background The ongoing outbreak of 2019 novel coronavirus disease (COVID-19) is a global threat. Clarifying its clinical features such as risk factors for disease progression is a pressing issue. We analyzed the difference between non-severe and severe cases with COVID-19 as a result of the mass infection on a cruise ship \u201cDiamond Princess\u201d in Japan. Methods In this retrospective, single-center study, total 104 cases of laboratory-confirmed COVID-19 were enrolled from the mass infection on the cruise ship from 11th to 25th Feb, 2020, at Self-Defense Forces Central Hospital in Japan. Clinical records, laboratory data, and radiological findings were collected and analyzed. Clinical outcomes were followed up until 26th Feb, 2020. Findings Of the 104 patients, 47 were male. The median age was 68 years. During the observation period, eight patients deteriorated into the severe cases. Finally, 76 and 28 patients were classified as non-severe (asymptomatic, mild), and severe cases, respectively. Chest CT abnormalities were found in 43 in non-severe cases and 23 in severe cases. The prevalence of consolidation on chest CT scan and lymphopenia on the admission day was significantly higher in severe cases and in the eight cases which worsened into severe disease during the observation period. Interpretation The high proportion of non-severe cases corrects the assessment of the trend of the outbreak. Consolidation on chest CT scan and lymphopenia were possible risk factors for deterioration of COVID-19 and contribute to the clinical management. Funding Not applicable.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nNot applicable.\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.18.20038125v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.18.20038125v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.18.20038125v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/20/2020.03.18.20038125.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.18.20038125v1", "access_rights": "restricted", "authors": ["Sakiko Tabata", "Kazuo Imai", "Shuichi Kawano", "Mayu Ikeda", "Tatsuya Kodama", "Kazuyasu Miyoshi", "Hirofumi Obinata", "Satoshi Mimura", "Tsutomu Kodera", "Manabu Kitagaki", "Michiya Sato", "Satoshi Suzuki", "Toshimitsu Ito", "Yasuhide Uwabe", "Kaku Tamura"]}